JC virus

JC virus
Marvin 101 · CC BY-SA 2.0 de · source
Name	JC virus
Virus group	DNA virus
Familia	Polyomaviridae
Genus	Betapolyomavirus
Species	Human polyomavirus 2

JC virus is a human polyomavirus first isolated in 1971 and linked to progressive multifocal leukoencephalopathy in immunocompromised patients. It infects oligodendrocytes and can remain latent in kidney, lymphoid tissue, and brain, reactivating under immunosuppression. Research spans virology, neurology, oncology, and transplantation medicine, involving numerous institutions and investigators.

Virology

JC virus is a small, non-enveloped, double-stranded DNA virus in the family Polyomaviridae and genus Betapolyomavirus. Its circular genome encodes early regulatory proteins (large T antigen) and late structural proteins (VP1, VP2, VP3) characterized in laboratories such as the National Institutes of Health, Centers for Disease Control and Prevention, and academic centers like Johns Hopkins Hospital and Mayo Clinic. Structural studies using cryo-electron microscopy at facilities including Max Planck Society and EMBL revealed capsid organization similar to BK virus and SV40. Viral entry involves interactions with cell surface receptors characterized in studies at Harvard University and Stanford University School of Medicine, including attachment to sialylated glycans and 5-HT2A receptor pathways analyzed in publications from University of California, San Francisco. The regulatory region shows archetype and rearranged variants identified in cohorts at Karolinska Institutet and University College London.

Epidemiology

Seroprevalence studies by teams at World Health Organization-collaborating centers, Columbia University, and Imperial College London indicate exposure rates varying by region and age, with many adults seropositive in surveys from Japan, United States, France, Brazil, and South Africa. Transmission routes were investigated in epidemiologic work by London School of Hygiene and Tropical Medicine and University of Toronto, implicating respiratory and fecal-oral patterns and associations with institutions such as daycare centers and long-term care facilities in outbreak analyses carried out with public health agencies like the Public Health England. Reactivation risk was characterized in transplant cohorts at Cleveland Clinic and Mount Sinai Health System, and among patients treated with monoclonal antibodies including therapies developed by Roche, Biogen, and Novartis studied in trials at M.D. Anderson Cancer Center and Penn Medicine. Geographic variation in molecular subtypes was mapped in collaborations with Pasteur Institute and National University of Singapore.

Pathogenesis and Clinical Manifestations

Pathogenesis research by neurologists at Massachusetts General Hospital and virologists at Cold Spring Harbor Laboratory shows viral tropism for glial cells leading to demyelination. In the central nervous system, infection of oligodendrocytes causes focal white matter lesions recognized by neuroradiologists at Toronto Western Hospital and Royal Melbourne Hospital. Clinical manifestations described in case series from Mayo Clinic and University of California, Los Angeles include progressive motor deficits, cognitive decline, visual disturbances, and ataxia documented in cohorts treated at University of Pennsylvania Health System. Immune reconstitution inflammatory syndrome following checkpoint blockade or antiretroviral therapy has been reported by teams at University of Cape Town and Beth Israel Deaconess Medical Center. Rare oncogenic associations were explored in studies at Memorial Sloan Kettering Cancer Center and Fred Hutchinson Cancer Center.

Diagnosis

Diagnostic modalities developed and validated at centers such as Johns Hopkins Hospital, Stanford Health Care, and the Mayo Clinic include polymerase chain reaction assays for viral DNA in cerebrospinal fluid, next-generation sequencing pipelines used at Broad Institute, and neuropathology protocols at The Rockefeller University. Neuroimaging criteria relying on MRI patterns were standardized in consensus statements from neuroradiology groups at American College of Radiology and European Society of Radiology. Brain biopsy with immunohistochemistry for viral proteins was refined at University of Oxford and University of Cambridge. Serologic assays for VP1 antibodies were employed in epidemiologic studies at Karolinska Institutet and University of Barcelona.

Treatment and Management

No antiviral therapy has proven definitively curative; management principles developed at transplant centers such as Cleveland Clinic and cancer centers like Memorial Sloan Kettering Cancer Center focus on immune reconstitution. Strategies include reducing immunosuppression used in protocols developed at Mount Sinai, and discontinuation of implicated monoclonal antibodies derived from pharmaceutical developers including Biogen and Roche. Experimental treatments evaluated in trials at National Institutes of Health and University of California, San Francisco include antiviral candidates, adoptive T cell therapies pioneered at Fred Hutchinson Cancer Center, and immune-modulating approaches studied at Dana-Farber Cancer Institute. Supportive care guidelines come from professional societies including Infectious Diseases Society of America and American Academy of Neurology.

Prevention and Public Health Implications

Prevention efforts emphasize risk stratification in populations managed by transplant programs at Cleveland Clinic and infusion centers at Massachusetts General Hospital, screening protocols developed at European Centre for Disease Prevention and Control and Public Health England, and pharmacovigilance for therapies produced by Novartis and Roche. Public health implications were examined during the rollout of monoclonal antibody therapies for multiple sclerosis in collaborative safety reviews involving Food and Drug Administration and European Medicines Agency. Vaccine research has been pursued at institutions such as Pasteur Institute and Johns Hopkins Bloomberg School of Public Health though no licensed vaccine exists. Ongoing surveillance is coordinated through networks involving World Health Organization, national public health agencies, and specialty societies including American Society of Transplantation.

Category:Polyomaviridae